Treatment Effectiveness, Disease Outcomes and Biological Response Modifiers - A Repeated-Measure Post-Treatment Insight Among Rheumatoid Arthritis Patients

Abstract

This study aimed to evaluate treatment effectiveness of Biologic Response Modifiers (BRMs)
and their impact on overall disease control and management among rheumatoid arthritis (RA) patients being treated with BRMs. The study was performed among 153 RA patients and disease activity score (DAS)
were calculated using DAS 28. Descriptive and inferential statistics were used to obtained the results. The
finding indicated that around 73.9% of the studied RA patients were treated with TNF inhibitors and 26.1%
were treated with non-TNF inhibitors. The post-treatment effect of BRMs regarding disease control and
management was measured at three different times intervals using the DAS 28. The obtained results showed
that mean DAS 28 scores were statistically significant and different after the 3 studied time intervals. In
conclusion, this post-treatment study confirmed that RA patients received optimum medication therapy with
BRMs (TNF inhibitors and/or non-TNF inhibitors) and achieved significant therapy response and overall
improvement in disease outcomes.